Literature DB >> 24231436

Higher revision and complication rates following total hip arthroplasty in patients with inflammatory bowel disease.

Bhaveen H Kapadia1, Kimona Issa1, Nupur Nagrare1, Robert Pivec1, Samik Banerjee1, Michael A Mont1.   

Abstract

The purpose of this study was to compare the clinical outcomes of total hip arthroplasty in patients with and without inflammatory bowel disease (IBD). Between 2001 and 2010, all total hip arthroplasties performed at a single institution were reviewed to identify patients who had IBD. There were 23 total hip arthroplasties in the study group, which were matched in a 1:3 ratio to 69 additional hips. At a mean follow-up of 49 months (range, 24-96 months), patients with IBD had an overall significantly lower survivorship of 87% (n = 3 revisions), compared to 98.5% (n = 1 revision) in the matched group who had a mean follow-up of 47 months (range, 24-94 months). In addition, there were significantly higher major complications in the study group (5 patients) compared to the matched group (2 patients). These results indicate that patients with IBD had an overall higher revision and complication rate.
© 2014.

Entities:  

Keywords:  Crohn's disease; complications; inflammatory bowel disease; revision; total hip arthroplasty; ulcerative colitis

Mesh:

Year:  2013        PMID: 24231436     DOI: 10.1016/j.arth.2013.07.011

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  8 in total

1.  Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease.

Authors:  Vineet S Rolston; Anish V Patel; Thomas J Learch; Dalin Li; Dmitry Karayev; Chadwick Williams; Madhavi L Siddanthi; Stephan R Targan; Michael H Weisman; Dermot P B McGovern
Journal:  J Clin Rheumatol       Date:  2019-01       Impact factor: 3.517

2.  Renal and Gastrointestinal Considerations in Joint Replacement Surgery.

Authors:  Benjamin Voss; Alexander Kurdi; Alexander Skopec; Jasmine Saleh; Mouhanad M El-Othmani; Joseph M Lane; William M Mihalko; Khaled J Saleh
Journal:  J Nat Sci       Date:  2015-02-01

3.  The utility of machine learning algorithms for the prediction of patient-reported outcome measures following primary hip and knee total joint arthroplasty.

Authors:  Christian Klemt; Akachimere Cosmas Uzosike; John G Esposito; Michael Joseph Harvey; Ingwon Yeo; Murad Subih; Young-Min Kwon
Journal:  Arch Orthop Trauma Surg       Date:  2022-06-29       Impact factor: 3.067

4.  The association of inflammatory bowel disease and immediate postoperative outcomes following lumbar fusion.

Authors:  Joseph E Tanenbaum; Stephanie T Kha; Edward C Benzel; Michael P Steinmetz; Thomas E Mroz
Journal:  Spine J       Date:  2017-11-15       Impact factor: 4.166

5.  Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis.

Authors:  Jurij Hanzel; Ahmed Almradi; Alexandra C Istl; Mei Lucy Yang; Katherine A Fleshner; Claire E Parker; Leonardo Guizzetti; Christopher Ma; Siddharth Singh; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2021-02-26       Impact factor: 3.199

6.  The risk of revision following total hip arthroplasty in patients with inflammatory bowel disease, a registry based study.

Authors:  Meghan M Moran; Peter Wessman; Ola Rolfson; Daniel D Bohl; Johan Kärrholm; Ali Keshavarzian; D Rick Sumner
Journal:  PLoS One       Date:  2021-11-04       Impact factor: 3.240

7.  Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty.

Authors:  Martin H Gregory; Andrew McKinnon; Dustin Stwalley; Kirk J Hippensteel; Edward V Loftus; Matthew A Ciorba; Margaret A Olsen; Parakkal Deepak
Journal:  J Crohns Colitis       Date:  2019-02-01       Impact factor: 9.071

8.  Hospital costs, length of stay and prevalence of hip and knee arthroplasty in patients with inflammatory bowel disease.

Authors:  Eli D Ehrenpreis; Ying Zhou
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.